For many patients navigating the complex landscape of hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD), the typical clinic appointment is a frantic triage of priorities. Discussions center on subluxations, chronic fatigue, autonomic dysfunction, and pain management. In this environment, sexual health is frequently relegated to the shadows—viewed either as a secondary concern or a topic too intimate to broach with a provider who is already overwhelmed by a patient’s multi-systemic symptoms.
However, a landmark study published in Frontiers in Reproductive Health by researchers at the Mayo Clinic’s EDS Clinic in Florida is challenging this silence. By analyzing data from over 1,400 patients, the study provides the most comprehensive evidence to date that sexual dysfunction is not merely a common co-morbidity for those with hypermobility, but a significant clinical issue that demands dedicated attention and professional intervention.
Main Facts: A New Baseline for Understanding
The research, which examined data collected between 2020 and 2025, aimed to move beyond anecdotal evidence to quantify the prevalence of sexual impairment in the hypermobile population. Unlike previous studies that might compare patients to the general healthy population, this study utilized a control group of patients with chronic pain who do not have a hypermobility diagnosis. This distinction is crucial; it isolates the specific impact of hEDS and HSD from the broader, well-documented challenges that accompany any chronic, painful condition.
The findings are stark: 69% of the study participants were diagnosed with HSD, 17% with hEDS, and 14% served as chronic pain controls. With a demographic skew consistent with these conditions, 90% of the participants were female. The data revealed that women with hEDS, in particular, face a disproportionately high burden of sexual health challenges, ranging from diminished interest to chronic pain, suggesting that the structural and systemic nature of connective tissue disorders plays a direct role in reproductive and sexual wellbeing.
Chronology of the Research
The path to this discovery began with the growing clinical observation by providers at the Mayo Clinic that patients were silently struggling with intimate issues that significantly impacted their quality of life.
- 2020–2025 (Data Collection Phase): The Mayo Clinic Florida EDS Clinic initiated a standardized screening process for all patients, utilizing a validated questionnaire covering eight key domains: sexual interest, sexual pain, orgasm difficulty, sexual anxiety, sexual pleasure, vaginal dryness (for women), and erectile difficulty (for men).
- Late 2026 (Analysis and Synthesis): Researchers aggregated the 1,407 responses to map the prevalence of these issues against the specific diagnoses of the patients.
- November 2026 (Publication): The study was released to the public, providing a empirical foundation for what has long been a whispered reality in the patient community.
- Post-Publication Era: The study has since served as a call to action for rheumatologists, gynecologists, and urologists to integrate sexual health screenings into the standard of care for patients with connective tissue disorders.
Supporting Data: The Disparity in Experience
The data provides a clear roadmap of how these conditions manifest differently across gender and diagnosis.
The Female Experience in hEDS
For women with hEDS, the numbers are sobering. Nearly 70% of these patients reported sexual problems, significantly higher than the 57% reported by the chronic pain control group. When broken down by category, the disparity remains consistent:
- Sexual Interest: 41% of hEDS patients vs. 30% of controls.
- Sexual Pain (Dyspareunia): 45% of hEDS patients vs. 31% of controls.
- Orgasm Difficulty: 34% of hEDS patients vs. 23% of controls.
The study also identified a high incidence of genitourinary symptoms. Women with hEDS were significantly more likely than their male counterparts to experience recurrent urinary tract infections (37.1%), urinary incontinence (30%), and pelvic floor dysfunction (26.7%). These findings suggest a strong correlation between connective tissue laxity in the pelvic floor and the functional sexual impairments reported by these patients.
The Male Experience: A Different Narrative
One of the study’s most provocative findings is the lack of statistical difference between men with hEDS and male chronic pain controls. Across all eight categories, including erectile function, men with hEDS did not report higher rates of impairment than those with other forms of chronic pain. This finding is vital for two reasons: it challenges the assumption that all aspects of life are uniformly impacted by the hEDS diagnosis, and it highlights that the specific, intense sexual impairment observed in women with hEDS may be linked to unique biological or hormonal factors, such as the pelvic structural differences inherent to female anatomy.
HSD vs. hEDS
While patients with HSD also reported higher levels of distress regarding sexual interest—39.5% for women and 33.3% for men—they did not show the same widespread dysfunction across other categories seen in the hEDS cohort. This suggests that while hypermobility is a spectrum, the specific structural integrity issues defining hEDS may place those patients at a higher risk for pelvic-related sexual pain and dysfunction.
Official Responses and Clinical Implications
The medical community has long acknowledged that chronic pain creates a "barrier to intimacy," but this study necessitates a shift toward a more proactive, specialized approach.
Dr. Jacqueline Moltzau Anderson, a researcher at the University of California who contributed to the dissemination of these findings, emphasizes that these figures are likely an underestimate. "When you consider that even our control group was comprised of people with chronic pain, we are measuring against an already affected baseline," she notes. "The reality is that for women with hEDS, the barriers to a healthy sexual life are multifaceted—involving not just pain, but also autonomic dysfunction, mast cell activation, and the simple, profound exhaustion of managing a multisystemic condition."
The authors of the study argue that the "wait and see" approach is no longer acceptable. They recommend that clinicians:
- Normalize the Conversation: Proactively ask about sexual health during intake to remove the stigma and the burden of the patient having to raise the topic.
- Multidisciplinary Referral: Create direct pathways to specialists, specifically pelvic floor physical therapists, who can address the mechanical instability of the pelvic girdle.
- Holistic Evaluation: Screen for comorbid conditions like endometriosis or pelvic congestion syndrome, which can mimic or exacerbate the symptoms of EDS/HSD.
Implications for the Future of Patient Care
The implications of this research extend far beyond the exam room. For the patient, validation is the first step toward recovery. Understanding that sexual dysfunction is a recognized, documented symptom of hEDS—rather than a psychological failure or a "private problem"—can alleviate the shame that often accompanies these conditions.
However, the authors also offer a necessary caveat: caution must be exercised. Not all pain in the pelvic region is a direct consequence of hEDS. By attributing every symptom to a connective tissue disorder, providers risk missing other critical, treatable conditions like endometriosis or infections. The study underscores that while hEDS/HSD may predispose patients to certain sexual health struggles, every patient deserves a thorough, individualized diagnostic process.
A New Standard of Care
Moving forward, the integration of sexual health into the broader EDS/HSD treatment model is essential. This includes:
- Education: Training providers to recognize the connection between pelvic floor instability and sexual dysfunction.
- Resources: Providing patients with access to specialized physical therapy that understands the unique needs of hypermobile tissues.
- Research: Expanding studies to include larger, more diverse cohorts, particularly in the male population, to better understand the nuances of the condition.
In conclusion, the findings from the Mayo Clinic represent a watershed moment in the advocacy for patients with hypermobility. By bringing these issues into the light, the researchers have provided the tools necessary to transform sexual health from a neglected, uncomfortable subject into a vital component of the comprehensive care that every patient with hEDS and HSD deserves. The path forward is one of openness, clinical rigor, and the firm belief that sexual wellbeing is an integral, non-negotiable part of a patient’s overall quality of life.
